



CODING AND BILLING GUIDE

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

YESINTEK (ustekinumab-kfce) is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy; active psoriatic arthritis (PsA); moderately to severely active Crohn's disease (CD); moderately to severely active ulcerative colitis.

Pediatric patients 6 years and older with: moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy; active psoriatic arthritis (PsA).

Please refer to the Dosage and Administration section of the [Full Prescribing Information](#) and to the [Instructions for Use](#) for complete information on how to prepare and administer YESINTEK. Please see Important Safety Information for YESINTEK on pages 41 and 42.

IMPORTANT SAFETY INFORMATION

Contraindications

YESINTEK is contraindicated in patients with clinically significant hypersensitivity to ustekinumab or to any of the excipients.

Infections

YESINTEK may increase the risk of infections and reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections in patients receiving ustekinumab.

Table of Contents

Introduction

Indications.....	1
Purpose of This Guide.....	3
Disclaimer + Reimbursement Support	3
Available Formulations of YESINTEK.....	4

Crohn's Disease and Ulcerative Colitis— YESINTEK Intravenous (IV) Induction

Dosing and Administration	6
Coding.....	7
Sample Claim Forms	13

Crohn's Disease and Ulcerative Colitis— Subcutaneous Maintenance Injection

Dosing and Administration	16
Coding.....	18
Sample Claim Forms	22

Plaque Psoriasis and Psoriatic Arthritis— YESINTEK Subcutaneous Injection

Dosing and Administration	25
Coding.....	27
Sample Claim Forms	32

Coverage & Support

Coverage Considerations	35
My Biocon Biologics™	38
Appendix.....	39

Important Safety Information

Important Safety Information.....	41
References	43

Purpose of This Guide

This Coding and Billing Guide for YESINTEK (ustekinumab-kfce) is intended to support medically appropriate patient access by providing general information on coding, coverage, billing, and reimbursement to healthcare professionals and their staff who prescribe and administer YESINTEK at physician offices and hospital outpatient sites of care. YESINTEK is biosimilar to Stelara® (ustekinumab) for the indications listed.

Disclaimer

The content provided in this guide is for informational purposes only and is not intended as legal advice or to replace a medical provider's professional judgment.

It is the sole responsibility of the treating healthcare professional to confirm coverage, coding, and claim submission guidance with the patient's health insurance plan to ensure YESINTEK claims are accurate, complete, and supported by documentation in the patient's medical record. Biocon Biologics does not guarantee that payers will consider all codes appropriate for all encounter scenarios, and Biocon Biologics does not guarantee YESINTEK coverage or reimbursement.

Please note that information specific to coding, coverage policies, and payment methodologies is subject to change and should be verified for each patient prior to treatment. The information in this guide is current as of February 2025.

Reimbursement Support

Information regarding access and reimbursement support resources for YESINTEK is available through My Biocon Biologics at 1-833-61-BIOCON. Or you can visit www.YesintekHCP.com.

Available Formulations of YESINTEK

Single-dose vial
for intravenous (IV) infusion*




DOSE:
130 mg/26 mL (5 mg/mL) VIAL

NDC: 83257-026-11

*IV dose not approved for all indications.


Single-dose vial
for subcutaneous injection



DOSE:
45 mg/0.5 mL VIAL

NDC: 83257-024-11

Single-dose prefilled syringe
for subcutaneous injection



45 mg/0.5 mL single-dose prefilled syringe

90 mg/mL single-dose prefilled syringe

DOSE:
45 mg/0.5 mL PREFILLED SYRINGE

NDC: 83257-023-41

90 mg/mL PREFILLED SYRINGE

NDC: 83257-025-41



CROHN'S DISEASE AND ULCERATIVE COLITIS

YESINTEK INTRAVENOUS (IV) INDUCTION

Indicated for adult patients with: moderately to severely active Crohn's disease (CD);
moderately to severely active ulcerative colitis.¹

Dosing and Administration¹

For the treatment of Crohn's disease or ulcerative colitis, YESINTEK is administered in 2 phases: induction and maintenance. Table 1 summarizes the induction doses, provided as a single intravenous infusion.

Induction

Intravenous (IV) Induction: A single IV infusion dose of YESINTEK using a weight-based dosage regimen (see Table 1).

Indications	Patient Weight	Dose*	Number of 130 mg/26 mL (5 mg/mL) YESINTEK Vials
Crohn's disease or ulcerative colitis	55 kg or less	260 mg	2 vials
	More than 55 kg to 85 kg	390 mg	3 vials
	More than 85 kg	520 mg	4 vials



Single-dose vial for intravenous (IV) infusion

Preparation and Administration of YESINTEK 130 mg/26 mL (5 mg/mL) Vial for IV Infusion¹

YESINTEK solution for IV infusion must be diluted, prepared, and infused by a healthcare professional using aseptic technique.

- Calculate the dose and the number of YESINTEK vials needed based on patient weight (Table 1). Each 26 mL vial of YESINTEK contains 130 mg of ustekinumab-kfce.
- Withdraw and then discard a volume of the 0.9% Sodium Chloride Injection, USP from the 250 mL infusion bag equal to the volume of YESINTEK to be added (discard 26 mL sodium chloride for each vial of YESINTEK needed, for 2 vials—discard 52 mL, for 3 vials—discard 78 mL, for 4 vials—discard 104 mL). Alternatively, a 250 mL infusion bag containing 0.45% Sodium Chloride Injection, USP may be used.
- Withdraw 26 mL of YESINTEK from each vial needed and add it to the 250 mL infusion bag. The final volume in the infusion bag should be 250 mL. Gently mix.
- Visually inspect the diluted solution before infusion. Do not use if visibly opaque particles, discoloration, or foreign particles are observed.
- Infuse the diluted solution over a period of at least 1 hour. Once diluted, the infusion should be completely administered within 4 hours of the dilution in the infusion bag.
- Use only an infusion set with an inline, sterile, non-pyrogenic, low protein-binding filter (pore size 0.2 micrometers).
- Do not infuse YESINTEK concomitantly in the same intravenous line with other agents.
- YESINTEK does not contain preservatives. Each vial is for one-time use in only one patient. Discard any remaining solution. Dispose any unused medicinal product in accordance with local requirements.

⁶ | Please refer to the Dosing and Administration section of the [Full Prescribing Information](#) and to the [Instructions for Use](#) for complete information on how to prepare and administer YESINTEK. Please see Important Safety Information for YESINTEK on pages 41 and 42.



Coding

The initial dose of YESINTEK for Crohn's disease or ulcerative colitis is delivered by IV infusion. This section of the Coding and Billing Guide will provide coding and product information related to that service.

ICD-10-CM Diagnosis Codes

YESINTEK is FDA approved for the treatment of Crohn's disease and ulcerative colitis. This table includes code ranges and codes that may be applicable for these indications; additional codes may apply. For the code ranges represented here, it is necessary to code to the greatest level of specificity; a code is invalid if it does not include the full number of required characters.²

*These codes are not intended to be promotional, nor to encourage or suggest a use of the drug that is inconsistent with FDA-approved use. The codes provided are not exhaustive and additional codes may apply.

[†]See <https://www.icd10data.com/ICD10CM/Codes/K00-K95/K50-K52/K50-#K50.01> for specific Crohn's Disease complication codes.

[‡]See <https://www.icd10data.com/ICD10CM/Codes/K00-K95/K50-K52/K51-> for specific Ulcerative Colitis complication codes.

TABLE 2. ICD-10-CM DIAGNOSIS CODES*—CROHN'S DISEASE AND ULCERATIVE COLITIS

Crohn's Disease ³	
K50.00	Crohn's disease of small intestine without complications
K50.011-K50.019 [†]	Crohn's disease of small intestine with complications
K50.10	Crohn's disease of large intestine without complications
K50.111-K50.119 [†]	Crohn's disease of large intestine with complications
K50.80	Crohn's disease of both small and large intestine without complications
K50.811-K50.812 [†]	Crohn's disease of both small and large intestine with complications
K50.90	Crohn's disease unspecified without complications
K50.911-K50.919 [†]	Crohn's disease unspecified with complications
Ulcerative Colitis ⁴	
K51.00	Ulcerative (chronic) pancolitis without complications
K51.011-K51.019 [‡]	Ulcerative (chronic) pancolitis with complications
K51.20	Ulcerative (chronic) proctitis without complications
K51.211-K51.219 [‡]	Ulcerative (chronic) proctitis with complications
K51.30	Ulcerative (chronic) rectosigmoiditis without complications
K51.311-K51.319 [‡]	Ulcerative (chronic) rectosigmoiditis with complications
K51.50	Left sided colitis without complications
K51.511-K51.519 [‡]	Left sided colitis with complications
K51.80	Other ulcerative colitis without complications
K51.811-K51.819 [‡]	Other ulcerative colitis with complications
K51.90	Ulcerative colitis, unspecified, without complications
K51.911-K51.919 [‡]	Ulcerative colitis, unspecified, with complications

7 | Please refer to the Dosage and Administration section of the Full Prescribing Information and to the Instructions for Use for complete information on how to prepare and administer YESINTEK. Please see Important Safety Information for YESINTEK on pages 41 and 42.



Coding (continued)

Healthcare Common Procedure Coding System (HCPCS) Level II Product Codes

HCPCS Level II product codes are used to report FDA-approved biologic products. The Centers for Medicare and Medicaid Services (CMS) has not yet assigned a product-specific HCPCS code for YESINTEK. Therefore, until a specific code is assigned, report YESINTEK for IV use with an unspecified HCPCS code. When reporting unspecified codes on claims, additional information may be required to be reported, including the NDC, strength and dose, and route of administration. Refer to your payer's documentation for additional information on billing unspecified HCPCS codes. An application for a product-specific HCPCS code for YESINTEK for IV use has been submitted.



Single-dose vial for intravenous (IV) infusion

TABLE 3. HCPCS CODES FOR YESINTEK⁵

HCPCS Code	Description	For	Site of Care
J3490	Unclassified drugs	YESINTEK, for intravenous injection	All sites of care
J3590	Biologic not otherwise classified	YESINTEK, for intravenous injection	All sites of care
C9399	Unclassified drugs or biologics	YESINTEK, for intravenous injection	Hospital outpatient department

Each 1 mg dose of YESINTEK (IV) equals 1 billing unit, thus a 130 mg vial of drug represents 130 units of J3590. Inaccurate reporting of drug billing units is a common claims error and can result in denied or delayed payment. When coding for J3590, report the total number of 1 mg increments administered.

It is the healthcare provider's responsibility to determine the appropriate codes, units, and modifiers. Coverage, billing, and reimbursement policies may vary by payer, plan, and setting of care. Contact your payer for additional information on coverage and billing for YESINTEK.

Coding (continued)

The initial dose of YESINTEK for Crohn's disease or ulcerative colitis is delivered by IV infusion. This section of the Coding and Billing Guide will provide coding and product information related to that service.

National Drug Code (NDC)

Drugs and biologics approved by the FDA are assigned a 3-segment NDC number that is specific to the labeler (manufacturer), product (a specific drug, strength, and dosage formulation), and package size. YESINTEK has been assigned a 10-digit NDC as listed in the prescribing information.⁶

Although the FDA uses a 10-digit format when registering NDCs, the 11-digit format is required by the Health Insurance Portability and Accountability Act (HIPAA) for claims submission without hyphens or other punctuation marks.

TABLE 4. NDC FOR YESINTEK (IV)¹

FDA-Specified 10-Digit NDC (5-3-2 format)	11-Digit NDC (5-4-2 format)	Description
83257-026-11	83257-0026-11	130 mg vial Single-use vial containing 130 mg (26 mL) of ustekinumab for IV infusion

NDC Units

The NDC unit of measure is determined by how the drug is supplied. In the outpatient setting, UN (unit) applies to drugs supplied in a vial in powder form, requiring reconstitution before administration, and ML (milliliters) applies to drugs supplied in liquid form.⁶ NDC units dispensed are based on the packaging and numeric quantity administered to the patient.

Accurate NDC coding typically requires reporting the following components⁶:

- The NDC with 11 digits in a 5-4-2 format (this may require converting a 10-digit NDC)
- The correct NDC unit of measure (ie, UN, ML)
- The number of NDC units administered
- The qualifier, N4, in front of the NDC

Example: the coding format for a 390 mg dose of YESINTEK IV from single-dose vials: **N483257002611 ML78**

Coding (continued)

HCPCS Level I / CPT Codes

Drug administration services are reported on claim forms in both the physician office (CMS-1500) and hospital outpatient (CMS-1450) sites of care using the CPT® coding system. The following codes may be used to report the intravenous administration of YESINTEK:

TABLE 5. CPT CODES FOR YESINTEK (IV) ADMINISTRATION⁷

Code	Description
96365	Intravenous infusion for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	IV infusion for therapy, prophylaxis, or diagnosis; each additional hour



Single-dose vial for intravenous (IV) infusion

It is the healthcare provider's responsibility to determine the appropriate codes, units, and modifiers. Coverage, billing, and reimbursement policies may vary by payer, plan, and setting of care. Contact your payer for additional information on coverage and billing for YESINTEK.

Revenue Codes

National Uniform Billing Committee (NUBC) hospital revenue codes are required to bill for hospital services and items like biologics. Each line item on a CMS-1450 (UB-04) or the 8371 electronic claim format, must have an assigned revenue code. The revenue codes below may be applicable to hospital claims for YESINTEK.

TABLE 6. REVENUE CODES FOR YESINTEK⁸

Code	Description
0260	IV Therapy, General
0636	Pharmacy, drugs requiring detailed coding

For additional support, you may visit YesintekHCP.com or contact us at 1-833-61-BIOCON.

CPT=current procedural technology.

10 | Please refer to the Dosage and Administration section of the [Full Prescribing Information](#) and to the [Instructions for Use](#) for complete information on how to prepare and administer YESINTEK. Please see Important Safety Information for YESINTEK on pages 41 and 42.



Coding (continued)

HCPCS and Current Procedural Technology (CPT®) Modifiers

Modifiers are used to report or indicate that a service or procedure has been altered by some specific circumstance, but not changed in its definition or code. They provide additional information about a service or procedure. Table 7 summarizes modifiers that may be applicable to coding and billing YESINTEK intravenous (IV) use in physician offices and hospital outpatient departments (HOPDs).

TABLE 7. SUMMARY OF CODE MODIFIERS

Modifier	Description	Indication and Placement	CMS-1500 (Item 24D)	CMS-1450 (Box 44)
25	Significant, separately identifiable evaluation and management (E/M) service by the same physician or other qualified healthcare professional on the same day of the procedure or other service ⁷	<ul style="list-style-type: none"> Reported if patient requires distinct E/M service in addition to the infusion procedure⁷ Must be substantiated by documentation that supports the relevant criteria for the reported E/M code⁷ Append the modifier to the appropriate E/M code⁷ 	✓ Required by Medicare	✓ Required by Medicare
PO*	Excepted services provided at an off-campus, outpatient, provider-based department of a hospital ⁵	<ul style="list-style-type: none"> To be reported on each claim line for excepted services furnished in an off-campus, provider-based department of a hospital and billed on an institutional claim⁹ 	N/A	✓ Required by Medicare
PN*	Non-excepted service provided at an off-campus, outpatient, provider-based department of a hospital ⁵	<ul style="list-style-type: none"> To be reported on each claim line for non-excepted services furnished in an off-campus provider-based department of a hospital and billed on an institutional claim⁹ 	N/A	✓ Required by Medicare
JW	Drug amount discarded/not administered to any patient ⁵	<ul style="list-style-type: none"> Applies only to the unused drug that is discarded after applicable dose has been administered from a single-use vial¹⁰ Append the modifier to the drug code on a line separate from that reporting the administered dose¹⁰ Required to be reported with unclassified HCPCS codes J3490 or J3590, when the product is administered in a physician's office or freestanding center¹⁰ Does not apply to C9399 reporting for hospital outpatient claims¹⁰ 	✓ Required by Medicare	✓ Required by Medicare
JZ	Zero drug amount discarded/not administered to any patient ⁵	<ul style="list-style-type: none"> To be used for single-dose containers or single-use packages when the entire amount has been administered to the patient (no wastage)¹¹ Required to be reported with unclassified HCPCS codes J3490 or J3590, when the product is administered in a physician's office or freestanding center¹⁰ Does not apply to C9399 reporting for hospital outpatient claims¹⁰ 	✓ Required by Medicare	✓ Required by Medicare
TB	Drug or biological acquired with 340B Drug Pricing Program discount ⁵	<ul style="list-style-type: none"> Must be reported by hospitals designated as "select entities" (rural sole community hospitals, children's hospitals, and PPS-exempt cancer hospitals) to identify 340B drugs for informational purposes⁹ To be reported on the same claim line as the drug HCPCS code for all 340B acquired drugs⁹ 	N/A	✓ Required by Medicare

*Neither the PO nor the PN modifier is to be reported for dedicated emergency departments, remote locations or satellite facilities of a hospital, or a provider-based department that is on campus.⁹

11 | Please refer to the Dosage and Administration section of the Full Prescribing Information and to the Instructions for Use for complete information on how to prepare and administer YESINTEK. Please see Important Safety Information for YESINTEK on pages 41 and 42.



Coding (continued)

Same-Day Evaluation and Management (E/M) Services

It may be necessary to provide E/M services on the same day as a drug administration procedure. Depending on the payer, E/M services that are medically necessary, separate and distinct from the drug administration procedure, and documented appropriately, are generally covered. CMS has a specific policy regarding use of CPT® code 99211 (level 1 medical visit for an established patient) in the physician office. The policy states: **CPT® code 99211 cannot be paid if it is billed, with or without modifier 25, with a chemotherapy or non-chemotherapy drug administration code.**¹²

Thus, CPT code 99211 cannot be paid by Medicare on the same day as an office-based infusion of YESINTEK.¹²

Payer policies vary. For information and assistance, please visit YesintekHCP.com or contact us at 1-833-61-BIOCON.



Single-dose vial
for intravenous (IV) infusion

12

Please refer to the Dosage and Administration section of the [Full Prescribing Information](#) and to the [Instructions for Use](#) for complete information on how to prepare and administer YESINTEK. Please see Important Safety Information for YESINTEK on pages 41 and 42.



Sample Claim Forms

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE MEDICAID TRICARE CHAMPVA GROUP HEALTH PLAN FECA BLK LUNG OTHER 1a. INSURED'S ID. NUMBER (For Program in Item 1)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial) Doe, Jane A. 3. PATIENT'S BIRTH DATE (MM | DD | YY) 01 | 15 | 52 M F 4. INSURED'S NAME (Last Name, First Name, Middle Initial) Doe, Jane A.

5. PATIENT'S ADDRESS (No., Street) 1234 Main Street 6. PATIENT RELATIONSHIP TO INSURED Spouse Child Other 7. INSURED'S ADDRESS (No., Street) 1234 Main Street

8. RESERVED FOR NUCC USE 9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial) 10. IS PATIENT'S CONDITION RELATED TO: 11. INSURED'S POLICY GROUP OR FECA NUMBER

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.

14. DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (LMP) 15. OTHER DATE QUAL. 16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM TO

17. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a. NPI 17b. NPI 123 456 7890 18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM TO

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC) 20. OUTSIDE LAB? YES NO \$ CHARGES

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Indicate ICD-9-CM code(s) to service line below (24E)) ICD Ind. 0 22. RESUBMISSION CODE ORIGINAL REF. NO.

23. PROVIDER NUMBER

DATE OF SERVICE	PLACE OF SERVICE	PROCEDURE, SERVICE, OR SUPPLY (CPT/HCPCS, MOONBER)	DIAGNOSIS POINTER	\$ CHARGES	DAYS OR UNITS	RENDERING PROVIDER ID.#
MM DD YY	MM DD YY	11	4 J3590	JZ	A	123 456 7890
MM DD YY	MM DD YY	11	96365	A	1	123 456 7890

25. FEDERAL TAX ID. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? (For gdn, drgms, pos baco) YES NO 28. TOTAL CHARGE \$ 29. AMOUNT PAID \$ 30. Rev'd for NUCC Use

31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREE OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.) 32. SERVICE FACILITY LOCATION INFORMATION 33. BILLING PROVIDER INFO & PH # (203) 555-6543

Dr. Jones
4231 Center Road
Anytown, AS 01010

123 456 7890

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

YESINTEK for IV Use

Physician Office Sample Claim Form (CMS-1500): 390 mg IV Induction Dose

- Box 19 ADDITIONAL CLAIM INFORMATION**
When billing an unclassified HCPCS product code such as J3590, Medicare and other payers may require additional information to be reported here, including the name of the drug, strength, and dosage. See your MAC for additional reporting requirements.
- Box 21 DIAGNOSIS**
Enter the appropriate diagnosis code (eg, K50.00 for Crohn's disease of small intestine without complications).
- Box 24A NDC INFORMATION**
If line item NDC information is required, it will be entered in the shaded portion on Row 1 of this section. Payer requirements for NDC entries may vary.
- Box 24D PROCEDURES/SERVICES/SUPPLIES**
Enter appropriate CPT and HCPCS codes and modifiers, if required. For example: YESINTEK J3590; Infusion Services CPT 96365.
Applicable Modifiers: See page 11.
- Box 24E DIAGNOSIS POINTER**
Enter the letter (A-L) from Box 21 for the diagnosis that corresponds to the line item. Enter only the diagnosis code(s) related to the service on a single line item.
- Box 24F \$ CHARGES**
Enter the total charges.
- Box 24G UNITS**
Enter the appropriate number of units of service.
• CPT 96365—Enter 1 unit for first hour of infusion
Subsequent time above an hour and a half would be reported with the add-on code 96366 with a unit count reflecting the amount of additional time.

It is the healthcare provider's responsibility to determine the appropriate codes and modifiers. Coverage, billing, and reimbursement policies may vary by payer, plan, and setting of care.

Sample Claim Forms (continued)

1 Anytown Hospital 160 Main Street Anytown, Anystate 01010		2 Pay-to-name Pay-to-address Pay-to-city/state		3a PAYER ID XX-XXXX		3b PAYER ID DOE 1234-97		4 BILL TO	
8 PATIENT NAME Doe, Jane A. (ID)		9 PATIENT ADDRESS 1234 Main Street		10 STATE IL		11 ZIP 101010		12 COUNTRY US	
13 BIRTHDATE 01-15-52		14 SEX F		15 ADMISSION DATE 12-15-22		16 CHARGE TYPE F		17 STATE	
18 OCCURRENCE DATE		19 CODE		20 OCCURRENCE DATE		21 CODE		22 OCCURRENCE DATE	
23 CODE		24 OCCURRENCE DATE		25 CODE		26 OCCURRENCE DATE		27 CODE	
28 OCCURRENCE DATE		29 CODE		30 OCCURRENCE DATE		31 CODE		32 OCCURRENCE DATE	
33 CODE		34 OCCURRENCE DATE		35 CODE		36 OCCURRENCE DATE		37 CODE	
38 OCCURRENCE DATE		39 CODE		40 OCCURRENCE DATE		41 CODE		42 OCCURRENCE DATE	
43 CODE		44 OCCURRENCE DATE		45 CODE		46 OCCURRENCE DATE		47 CODE	
48 OCCURRENCE DATE		49 CODE		50 OCCURRENCE DATE		51 CODE		52 OCCURRENCE DATE	
53 CODE		54 OCCURRENCE DATE		55 CODE		56 OCCURRENCE DATE		57 CODE	
58 OCCURRENCE DATE		59 CODE		60 OCCURRENCE DATE		61 CODE		62 OCCURRENCE DATE	
63 CODE		64 OCCURRENCE DATE		65 CODE		66 OCCURRENCE DATE		67 CODE	
68 OCCURRENCE DATE		69 CODE		70 OCCURRENCE DATE		71 CODE		72 OCCURRENCE DATE	
73 CODE		74 OCCURRENCE DATE		75 CODE		76 OCCURRENCE DATE		77 CODE	
78 OCCURRENCE DATE		79 CODE		80 OCCURRENCE DATE		81 CODE		82 OCCURRENCE DATE	
83 CODE		84 OCCURRENCE DATE		85 CODE		86 OCCURRENCE DATE		87 CODE	
88 OCCURRENCE DATE		89 CODE		90 OCCURRENCE DATE		91 CODE		92 OCCURRENCE DATE	
93 CODE		94 OCCURRENCE DATE		95 CODE		96 OCCURRENCE DATE		97 CODE	
98 OCCURRENCE DATE		99 CODE		100 OCCURRENCE DATE		101 CODE		102 OCCURRENCE DATE	
103 CODE		104 OCCURRENCE DATE		105 CODE		106 OCCURRENCE DATE		107 CODE	
108 OCCURRENCE DATE		109 CODE		110 OCCURRENCE DATE		111 CODE		112 OCCURRENCE DATE	
113 CODE		114 OCCURRENCE DATE		115 CODE		116 OCCURRENCE DATE		117 CODE	
118 OCCURRENCE DATE		119 CODE		120 OCCURRENCE DATE		121 CODE		122 OCCURRENCE DATE	
123 CODE		124 OCCURRENCE DATE		125 CODE		126 OCCURRENCE DATE		127 CODE	
128 OCCURRENCE DATE		129 CODE		130 OCCURRENCE DATE		131 CODE		132 OCCURRENCE DATE	
133 CODE		134 OCCURRENCE DATE		135 CODE		136 OCCURRENCE DATE		137 CODE	
138 OCCURRENCE DATE		139 CODE		140 OCCURRENCE DATE		141 CODE		142 OCCURRENCE DATE	
143 CODE		144 OCCURRENCE DATE		145 CODE		146 OCCURRENCE DATE		147 CODE	
148 OCCURRENCE DATE		149 CODE		150 OCCURRENCE DATE		151 CODE		152 OCCURRENCE DATE	
153 CODE		154 OCCURRENCE DATE		155 CODE		156 OCCURRENCE DATE		157 CODE	
158 OCCURRENCE DATE		159 CODE		160 OCCURRENCE DATE		161 CODE		162 OCCURRENCE DATE	
163 CODE		164 OCCURRENCE DATE		165 CODE		166 OCCURRENCE DATE		167 CODE	
168 OCCURRENCE DATE		169 CODE		170 OCCURRENCE DATE		171 CODE		172 OCCURRENCE DATE	
173 CODE		174 OCCURRENCE DATE		175 CODE		176 OCCURRENCE DATE		177 CODE	
178 OCCURRENCE DATE		179 CODE		180 OCCURRENCE DATE		181 CODE		182 OCCURRENCE DATE	
183 CODE		184 OCCURRENCE DATE		185 CODE		186 OCCURRENCE DATE		187 CODE	
188 OCCURRENCE DATE		189 CODE		190 OCCURRENCE DATE		191 CODE		192 OCCURRENCE DATE	
193 CODE		194 OCCURRENCE DATE		195 CODE		196 OCCURRENCE DATE		197 CODE	
198 OCCURRENCE DATE		199 CODE		200 OCCURRENCE DATE		201 CODE		202 OCCURRENCE DATE	
203 CODE		204 OCCURRENCE DATE		205 CODE		206 OCCURRENCE DATE		207 CODE	
208 OCCURRENCE DATE		209 CODE		210 OCCURRENCE DATE		211 CODE		212 OCCURRENCE DATE	
213 CODE		214 OCCURRENCE DATE		215 CODE		216 OCCURRENCE DATE		217 CODE	
218 OCCURRENCE DATE		219 CODE		220 OCCURRENCE DATE		221 CODE		222 OCCURRENCE DATE	
223 CODE		224 OCCURRENCE DATE		225 CODE		226 OCCURRENCE DATE		227 CODE	
228 OCCURRENCE DATE		229 CODE		230 OCCURRENCE DATE		231 CODE		232 OCCURRENCE DATE	
233 CODE		234 OCCURRENCE DATE		235 CODE		236 OCCURRENCE DATE		237 CODE	
238 OCCURRENCE DATE		239 CODE		240 OCCURRENCE DATE		241 CODE		242 OCCURRENCE DATE	
243 CODE		244 OCCURRENCE DATE		245 CODE		246 OCCURRENCE DATE		247 CODE	
248 OCCURRENCE DATE		249 CODE		250 OCCURRENCE DATE		251 CODE		252 OCCURRENCE DATE	
253 CODE		254 OCCURRENCE DATE		255 CODE		256 OCCURRENCE DATE		257 CODE	
258 OCCURRENCE DATE		259 CODE		260 OCCURRENCE DATE		261 CODE		262 OCCURRENCE DATE	
263 CODE		264 OCCURRENCE DATE		265 CODE		266 OCCURRENCE DATE		267 CODE	
268 OCCURRENCE DATE		269 CODE		270 OCCURRENCE DATE		271 CODE		272 OCCURRENCE DATE	
273 CODE		274 OCCURRENCE DATE		275 CODE		276 OCCURRENCE DATE		277 CODE	
278 OCCURRENCE DATE		279 CODE		280 OCCURRENCE DATE		281 CODE		282 OCCURRENCE DATE	
283 CODE		284 OCCURRENCE DATE		285 CODE		286 OCCURRENCE DATE		287 CODE	
288 OCCURRENCE DATE		289 CODE		290 OCCURRENCE DATE		291 CODE		292 OCCURRENCE DATE	
293 CODE		294 OCCURRENCE DATE		295 CODE		296 OCCURRENCE DATE		297 CODE	
298 OCCURRENCE DATE		299 CODE		300 OCCURRENCE DATE		301 CODE		302 OCCURRENCE DATE	
303 CODE		304 OCCURRENCE DATE		305 CODE		306 OCCURRENCE DATE		307 CODE	
308 OCCURRENCE DATE		309 CODE		310 OCCURRENCE DATE		311 CODE		312 OCCURRENCE DATE	
313 CODE		314 OCCURRENCE DATE		315 CODE		316 OCCURRENCE DATE		317 CODE	
318 OCCURRENCE DATE		319 CODE		320 OCCURRENCE DATE		321 CODE		322 OCCURRENCE DATE	
323 CODE		324 OCCURRENCE DATE		325 CODE		326 OCCURRENCE DATE		327 CODE	
328 OCCURRENCE DATE		329 CODE		330 OCCURRENCE DATE		331 CODE		332 OCCURRENCE DATE	
333 CODE		334 OCCURRENCE DATE		335 CODE		336 OCCURRENCE DATE		337 CODE	
338 OCCURRENCE DATE		339 CODE		340 OCCURRENCE DATE		341 CODE		342 OCCURRENCE DATE	
343 CODE		344 OCCURRENCE DATE		345 CODE		346 OCCURRENCE DATE		347 CODE	
348 OCCURRENCE DATE		349 CODE		350 OCCURRENCE DATE		351 CODE		352 OCCURRENCE DATE	
353 CODE		354 OCCURRENCE DATE		355 CODE		356 OCCURRENCE DATE		357 CODE	
358 OCCURRENCE DATE		359 CODE		360 OCCURRENCE DATE		361 CODE		362 OCCURRENCE DATE	
363 CODE		364 OCCURRENCE DATE		365 CODE		366 OCCURRENCE DATE		367 CODE	
368 OCCURRENCE DATE		369 CODE		370 OCCURRENCE DATE		371 CODE		372 OCCURRENCE DATE	
373 CODE		374 OCCURRENCE DATE		375 CODE		376 OCCURRENCE DATE		377 CODE	
378 OCCURRENCE DATE		379 CODE		380 OCCURRENCE DATE		381 CODE		382 OCCURRENCE DATE	
383 CODE		384 OCCURRENCE DATE		385 CODE		386 OCCURRENCE DATE		387 CODE	
388 OCCURRENCE DATE		389 CODE		390 OCCURRENCE DATE		391 CODE		392 OCCURRENCE DATE	
393 CODE		394 OCCURRENCE DATE		395 CODE		396 OCCURRENCE DATE		397 CODE	
398 OCCURRENCE DATE		399 CODE		400 OCCURRENCE DATE		401 CODE		402 OCCURRENCE DATE	
403 CODE		404 OCCURRENCE DATE		405 CODE		406 OCCURRENCE DATE		407 CODE	
408 OCCURRENCE DATE		409 CODE		410 OCCURRENCE DATE		411 CODE		412 OCCURRENCE DATE	
413 CODE		414 OCCURRENCE DATE		415 CODE		416 OCCURRENCE DATE		417 CODE	
418 OCCURRENCE DATE		419 CODE		420 OCCURRENCE DATE		421 CODE		422 OCCURRENCE DATE	
423 CODE		424 OCCURRENCE DATE		425 CODE		426 OCCURRENCE DATE		427 CODE	
428 OCCURRENCE DATE		429 CODE		430 OCCURRENCE DATE		431 CODE		432 OCCURRENCE DATE	
433 CODE		434 OCCURRENCE DATE		435 CODE		436 OCCURRENCE DATE		437 CODE	
438 OCCURRENCE DATE		439 CODE		440 OCCURRENCE DATE		441 CODE		442 OCCURRENCE DATE	
443 CODE		444 OCCURRENCE DATE		445 CODE		446 OCCURRENCE DATE		447 CODE	
448 OCCURRENCE DATE		449 CODE		450 OCCURRENCE DATE		451 CODE		452 OCCURRENCE DATE	
453 CODE		454 OCCURRENCE DATE		455 CODE		456 OCCURRENCE DATE		457 CODE	
458 OCCURRENCE DATE		459 CODE		460 OCCURRENCE DATE		461 CODE		462 OCCURRENCE DATE	
463 CODE		464 OCCURRENCE DATE		465 CODE		466 OCCURRENCE DATE		467 CODE	
468 OCCURRENCE DATE		469 CODE		470 OCCURRENCE DATE		471 CODE		472 OCCURRENCE DATE	
473 CODE		474 OCCURRENCE DATE		475 CODE		476 OCCURRENCE DATE		477 CODE	
478 OCCURRENCE DATE		479 CODE		480 OCCURRENCE DATE		481 CODE		482 OCCURRENCE DATE	
483 CODE		484 OCCURRENCE DATE		485 CODE		486 OCCURRENCE DATE		487 CODE	
488 OCCURRENCE DATE		489 CODE		490 OCCURRENCE DATE		491 CODE		492 OCCURRENCE DATE	
493 CODE		494 OCCURRENCE DATE		495 CODE		496 OCCURRENCE DATE		497 CODE	
498 OCCURRENCE DATE		499 CODE		500 OCCURRENCE DATE		501 CODE		502 OCCURRENCE DATE	
503 CODE		504 OCCURRENCE DATE		505 CODE		506 OCCURRENCE DATE		507 CODE	
508 OCCURRENCE DATE		509 CODE		510 OCCURRENCE DATE		511 CODE		512 OCCURRENCE DATE	
513 CODE		514 OCCURRENCE DATE		515 CODE		516 OCCURRENCE DATE		517 CODE	
518 OCCURRENCE DATE		519 CODE		520 OCCURRENCE DATE		521 CODE		522 OCCURRENCE DATE	
523 CODE		524 OCCURRENCE DATE		525 CODE		526 OCCURRENCE DATE		527 CODE	
528 OCCURRENCE DATE		529 CODE		530 OCCURRENCE DATE		531 CODE		532 OCCURRENCE DATE	
533 CODE		534 OCCURRENCE DATE		535 CODE		536 OCCURRENCE DATE		537 CODE	
538 OCCURRENCE DATE		539 CODE		540 OCCURRENCE DATE		541 CODE		542 OCCURRENCE DATE	
543 CODE		544 OCCURRENCE DATE		545 CODE		546 OCCURRENCE DATE		547 CODE	
548 OCCURRENCE DATE		549 CODE		550 OCCURRENCE DATE		551 CODE		552 OCCURRENCE DATE	
553 CODE		554 OCCURRENCE DATE		555 CODE		556 OCCURRENCE DATE		557 CODE	
558 OCCURRENCE DATE		559 CODE		560 OCCURRENCE DATE		561 CODE		562 OCCURRENCE DATE	
563 CODE		564 OCCURRENCE DATE		565 CODE		566 OCCURRENCE DATE		567 CODE	
568 OCCURRENCE DATE		569 CODE		570 OCCURRENCE DATE		571 CODE		572 OCCURRENCE DATE	
573 CODE		574 OCCURRENCE DATE		575 CODE		576 OCCURRENCE DATE		577 CODE	
578 OCCURRENCE DATE		579 CODE		580 OCCURRENCE DATE		581 CODE		582 OCCURRENCE DATE	
583 CODE		584 OCCURRENCE DATE		585 CODE		586 OCCURRENCE DATE		587 CODE	
588 OCCURRENCE DATE		589 CODE		590 OCCURRENCE DATE		591 CODE		592 OCCURRENCE DATE	
593 CODE		594 OCCURRENCE DATE		595 CODE		596 OCCURRENCE DATE		597 CODE	
598 OCCURRENCE DATE		599 CODE		600 OCCURRENCE DATE		601 CODE		602 OCCURRENCE DATE	
603 CODE		604 OCCURRENCE DATE		605 CODE		606 OCCURRENCE DATE		607 CODE	
608 OCCURRENCE DATE		609 CODE		610 OCCURRENCE DATE		611 CODE		612 OCCURRENCE DATE	
613 CODE		614 OCCURRENCE DATE		615 CODE		616 OCCURRENCE DATE		617 CODE	
618 OCCURRENCE DATE		619 CODE		620 OCCURRENCE DATE		621 CODE		622 OCCURRENCE DATE	
623 CODE		624 OCCURRENCE DATE		625 CODE		626 OCCURRENCE DATE		627 CODE	
628 OCCURRENCE DATE		629 CODE		630 OCCURRENCE DATE		631 CODE		632 OCCURRENCE DATE	
633 CODE		634 OCCURRENCE DATE		635 CODE		636 OCCURRENCE DATE		637 CODE	
638 OCCURRENCE DATE		639 CODE		640 OCCURRENCE DATE		641 CODE		642 OCCURRENCE DATE	
643 CODE		644 OCCURRENCE DATE		645 CODE		646 OCCURRENCE DATE		647 CODE	
648 OCCURRENCE DATE		649 CODE		650 OCCURRENCE DATE		651 CODE		652 OCCURRENCE DATE	
653 CODE		654 OCCURRENCE DATE		655 CODE		656 OCCURRENCE DATE		657 CODE	
658 OCCURRENCE DATE		659 CODE		660 OCCURRENCE DATE		661 CODE		662 OCCURRENCE DATE	
663 CODE		664 OCCURRENCE DATE		665 CODE		666 OCCURRENCE DATE		667 CODE	
668 OCCURRENCE DATE		669 CODE		670 OCCURRENCE DATE		671 CODE		672 OCCURRENCE DATE	
673 CODE		674 OCCURRENCE DATE		675 CODE		676 OCCURRENCE DATE		677 CODE	
678 OCCURRENCE DATE		679 CODE		680 OCCURRENCE DATE		681 CODE		682 OCCURRENCE DATE	
683 CODE		684 OCCURRENCE DATE		685 CODE		686 OCCURRENCE DATE		687 CODE	
688 OCCURRENCE DATE		689 CODE		690 OCCURRENCE DATE		691 CODE		692 OCCURRENCE DATE	
693 CODE		694 OCCURRENCE DATE		695 CODE		696 OCCURRENCE DATE		697 CODE	
698 OCCURRENCE DATE		699 CODE		700 OCCURRENCE DATE		701 CODE		702 OCCURRENCE DATE	
703 CODE		704 OCCURRENCE DATE		705 CODE		706 OCCURRENCE DATE		707 CODE	
708 OCCURRENCE DATE		709 CODE		710 OCCURRENCE DATE		711 CODE		712 OCCURRENCE DATE	
713 CODE		714 OCCURRENCE DATE		715 CODE		716 OCCURRENCE DATE		717 CODE	
718 OCCURRENCE DATE		719 CODE		720 OCCURRENCE DATE		721 CODE		722 OCCURRENCE DATE	
723 CODE		724 OCCURRENCE DATE		725 CODE		726 OCCURRENCE DATE		727 CODE	
728 OCCURRENCE DATE		729 CODE		730 OCCURRENCE DATE		731 CODE		732 OCCURRENCE DATE	
733 CODE		734 OCCURRENCE DATE		735 CODE		736 OCCURRENCE DATE		737 CODE	
738 OCCURRENCE DATE		739 CODE		740 OCCURRENCE DATE		741 CODE		742 OCCURRENCE DATE	
743 CODE		744 OCCURRENCE DATE		745 CODE		746 OCCURRENCE DATE			



CROHN'S DISEASE AND ULCERATIVE COLITIS

SUBCUTANEOUS MAINTENANCE INJECTION

Indicated for the treatment of adults with moderately to severely active Crohn's disease or moderately to severely active ulcerative colitis.¹

Dosing and Administration¹

Maintenance

The MAINTENANCE doses of YESINTEK for Crohn's disease or ulcerative colitis are delivered by subcutaneous injection.

Maintenance Dosage Regimen: The recommended maintenance dosage is a subcutaneous 90 mg dose administered 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.



Single-dose vial for subcutaneous injection

TABLE 1. MAINTENANCE YESINTEK DOSAGE¹

Indications	Dose	Frequency
Crohn's disease or ulcerative colitis	90 mg	<ul style="list-style-type: none"> • 8 weeks after initial IV • Every 8 weeks thereafter

There are 2 available formulations for the maintenance dosage regimen, NOT to be used for intravenous induction therapy:

- 90 mg/mL single-dose prefilled syringe
- 45 mg/0.5 mL single-use vial

Dosing and Administration¹ (continued)

This section of the Coding and Billing Guide will provide coding and product information related to the subcutaneous injection of the 45 mg/0.5 mL single-dose vial only.

Preparation and Administration of YESINTEK for Subcutaneous Injection

YESINTEK is intended for use under the guidance and supervision of a physician. YESINTEK should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician. The appropriate dose should be determined by a healthcare provider.

If a physician determines that it is appropriate, a patient may self-inject or a caregiver may inject YESINTEK after proper training in subcutaneous injection technique. Patients should be instructed to follow the directions provided in the [Instructions for Use](#).



Single-dose vial
for subcutaneous injection

General Considerations for Administration

- YESINTEK is intended for use under the guidance and supervision of a healthcare provider. YESINTEK should only be administered to patients who will be closely monitored and have regular follow-up visits with a healthcare provider. The appropriate dose should be determined by a healthcare provider using the patient's current weight at the time of dosing. In pediatric patients, it is recommended that YESINTEK be administered by a healthcare provider. If a healthcare provider determines that it is appropriate, a patient may self-inject or a caregiver may inject YESINTEK after proper training in subcutaneous injection technique. Instruct patients to follow the directions provided in the Instructions for Use.
- It is recommended that each injection be administered at a different anatomic location (such as upper arms, gluteal regions, thighs, or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, or indurated. When using the single-dose vial, a 1 mL syringe with a 27-gauge, ½-inch needle is recommended.
- Prior to administration, visually inspect YESINTEK for particulate matter and discoloration. YESINTEK is a clear, colorless to pale yellow solution. Do not use YESINTEK if it is discolored or cloudy, or if other particulate matter is present. YESINTEK does not contain preservatives; therefore, discard any unused product remaining in the vial and/or syringe.
- Each vial of YESINTEK for subcutaneous use contains 45 mg of ustekinumab in 0.5 mL. Determine the dose and number of YESINTEK vials needed based on the indication.
- Draw required dose using the Instructions for Use.

Coding

National Drug Code (NDC)

Drugs and biologics approved by the FDA are assigned a 3-segment NDC number that is specific to the labeler (manufacturer), product (a specific drug, strength, and dosage formulation), and package size. Branded YESINTEK and unbranded ustekinumab-kfce have been assigned 10-digit NDCs as listed in the prescribing information.⁶

Although the FDA uses a 10-digit format, the 11-digit format is required by HIPAA for claims submission without hyphens or punctuation marks.



Single-dose vial for subcutaneous injection

TABLE 2. YESINTEK SINGLE-DOSE VIAL FOR SUBCUTANEOUS INJECTION NDC¹

FDA-Specified 10-Digit NDC (5-3-2 format)	11-Digit NDC (5-4-2 format)	Description
83257-024-11	83257-0024-11	45 mg single-dose vial containing 45 mg of YESINTEK per 0.5 mL solution

NDC Units

The NDC unit of measure is determined by how the drug is supplied. In the outpatient setting, UN (unit) applies to drugs supplied in a vial in powder form, requiring reconstitution before administration, and ML (milliliters) applies to drugs supplied in liquid form.⁶ NDC units dispensed are based on the packaging and numeric quantity administered to the patient.

Accurate NDC coding typically requires reporting the following components⁶:

- The NDC with 11 digits in a 5-4-2 format (this may require converting a 10-digit NDC)
- The correct NDC unit of measure (ie, UN, ML)
- The number of NDC units dispensed
- The qualifier, N4, in front of the NDC

Example: the coding format for a 90 mg dose of YESINTEK from single-dose vials: **N483257002411 ML1**

Coding (continued)

Healthcare Common Procedure Code System (HCPCS) Level II Codes

HCPCS Level II product codes are used to report FDA-approved biologic products. The Centers for Medicare and Medicaid Services (CMS) has not yet assigned a product-specific HCPCS code for YESINTEK. Therefore, until a specific code is assigned, report YESINTEK for subcutaneous injection with an unspecified HCPCS code. When reporting unspecified codes on claims, additional information may be required to be reported, including the NDC, strength and dose, and route of administration. Refer to your payer's documentation for additional information on billing unspecified HCPCS codes. An application for a product-specific HCPCS code for YESINTEK for subcutaneous use has been submitted.



Single-dose vial for subcutaneous injection

TABLE 3. HCPCS CODES FOR YESINTEK⁵

Code	Description	For	Site of Care
J3490	Unclassified drugs	YESINTEK, subcutaneous injection	All sites of care
J3590	Biologic not otherwise classified	YESINTEK, subcutaneous injection	All sites of care
C9399	Unclassified drugs or biologics	YESINTEK, subcutaneous injection	Hospital outpatient department

It is the healthcare provider's responsibility to determine the appropriate codes, units, and modifiers. Coverage, billing, and reimbursement policies may vary by payer, plan, and setting of care. Contact your payer for additional information on coverage and billing for YESINTEK.

Coding (continued)

HCPCS Level I / Current Procedural Technology (CPT®) Codes

Drug administration services are reported on claim forms in both the physician office (CMS-1500) and hospital outpatient (CMS-1450) sites of care using the CPT coding system. The following code may be used to report the subcutaneous administration of YESINTEK:



Single-dose vial for subcutaneous injection

TABLE 4. CPT CODE FOR YESINTEK FOR SUBCUTANEOUS INJECTION⁷

Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous injection or intramuscular

Please refer to the summary of code modifiers on the next page for details.

It is the healthcare provider's responsibility to determine the appropriate codes, units, and modifiers. Coverage, billing, and reimbursement policies may vary by payer, plan, and setting of care. Contact your payer for additional information on coverage and billing for YESINTEK.

Revenue Codes

National Uniform Billing Committee (NUBC) hospital revenue codes are required to bill for hospital services and items like biologics. Each line item on a CMS-1450 (UB-04) or the 837I electronic claim format, must have an assigned revenue code. The revenue codes below may be applicable to hospital claims for YESINTEK for subcutaneous use:

TABLE 5. REVENUE CODES FOR YESINTEK FOR SUBCUTANEOUS INJECTION⁸

Code	Description
0636	Pharmacy, drugs requiring detailed coding
0940	Other therapeutic services - General

Coding (continued)

HCPCS and CPT Modifiers

Modifiers are used to report or indicate that a service or procedure has been altered by some specific circumstance, but not changed in its definition or code. They provide additional information about a service or procedure. Table 6 summarizes modifiers that may be applicable to coding and billing YESINTEK intravenous (IV) use in physician offices and hospital outpatient departments (HOPDs).

TABLE 6. SUMMARY OF CODE MODIFIERS

Modifier	Description	Indication and Placement	CMS-1500 (Item 24D)	CMS-1450 (Box 44)
25	Significant, separately identifiable evaluation and management (E/M) service by the same physician or other qualified healthcare professional on the same day of the procedure or other service ⁷	<ul style="list-style-type: none"> Reported if patient requires distinct E/M service in addition to the infusion procedure⁷ Must be substantiated by documentation that supports the relevant criteria for the reported E/M code⁷ Append the modifier to the appropriate E/M code⁷ 	✓ Required by Medicare	✓ Required by Medicare
PO*	Excepted services provided at an off-campus, outpatient, provider-based department of a hospital ⁵	<ul style="list-style-type: none"> To be reported on each claim line for excepted services furnished in an off-campus, provider-based department of a hospital and billed on an institutional claim⁹ 	N/A	✓ Required by Medicare
PN*	Non-excepted service provided at an off-campus, outpatient, provider-based department of a hospital ⁵	<ul style="list-style-type: none"> To be reported on each claim line for non-excepted services furnished in an off-campus provider-based department of a hospital and billed on an institutional claim⁹ 	N/A	✓ Required by Medicare
JW	Drug amount discarded/not administered to any patient ⁵	<ul style="list-style-type: none"> Applies only to the unused drug that is discarded after applicable dose has been administered from a single-use vial¹⁰ Append the modifier to the drug code on a line separate from that reporting the administered dose¹⁰ Required to be reported with unclassified HCPCS codes J3490 or J3590, when the product is administered in a physician's office or freestanding center¹⁰ Does not apply to C9399 reporting for hospital outpatient claims¹⁰ 	✓ Required by Medicare	✓ Required by Medicare
JZ	Zero drug amount discarded/not administered to any patient ⁵	<ul style="list-style-type: none"> To be used for single-dose containers or single-use packages when the entire amount has been administered to the patient (no wastage)¹¹ Required to be reported with unclassified HCPCS codes J3490 or J3590, when the product is administered in a physician's office or freestanding center¹⁰ Does not apply to C9399 reporting for hospital outpatient claims¹⁰ 	✓ Required by Medicare	✓ Required by Medicare
TB	Drug or biological acquired with 340B Drug Pricing Program discount ⁵	<ul style="list-style-type: none"> Must be reported by hospitals designated as "select entities" (rural sole community hospitals, children's hospitals, and PPS-exempt cancer hospitals) to identify 340B drugs for informational purposes⁹ To be reported on the same claim line as the drug HCPCS code for all 340B acquired drugs⁹ 	N/A	✓ Required by Medicare

*Neither the PO nor the PN modifier is to be reported for dedicated emergency departments, remote locations or satellite facilities of a hospital, or a provider-based department that is on campus.⁹

Sample Claim Forms

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE (Medicare#) MEDICAID (Medicaid#) TRICARE (TRICARE#) CHAMPVA (Member ID#) GROUP HEALTH PLAN (ID#) FECA (BLK/LUNG ID#) OTHER (ID#)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)
Doe, Jane A.

3. PATIENT'S BIRTH DATE (MM | DD | YY)
01 | 15 | 52 SEX M F

4. INSURED'S NAME (Last Name, First Name, Middle Initial)
Doe, Jane A.

5. PATIENT'S ADDRESS (No., Street)
1234 Main Street

6. PATIENT RELATIONSHIP TO INSURED
Self Spouse Child Other

7. INSURED'S ADDRESS (No., Street)
1234 Main Street

8. RESERVED FOR NUCC USE

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)

10. IS PATIENT'S CONDITION RELATED TO:

11. INSURED'S POLICY GROUP OR FECA NUMBER

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE: I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE: I authorize payment of medical benefits to the undersigned physician or supplier for services described below.

14. DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (LMP)
MM | DD | YY QUAL

15. OTHER DATE
MM | DD | YY QUAL

16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION
FROM MM | DD | YY TO MM | DD | YY

17. NAME OF REFERRING PROVIDER OR OTHER SOURCE
Dr. Smith

17a. NPI **123 456 7890**

18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES
FROM MM | DD | YY TO MM | DD | YY

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)

20. OUTSIDE LAB? YES NO \$ CHARGES

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate ICD to service line below (24E))
A. **K50.00** B. C. D. E. F. G. H. I.

22. RESUBMISSION CODE ORIGINAL REF. NO.

23. PROVIDER NUMBER

DATE OF SERVICE	PLACE OF SERVICE	PROCEDURE, SERVICE, OR SUPPLY (CPT/HCPCS MOONBER)	DIAGNOSIS POINTER	\$ CHARGES	DAYS OR UNITS	RENDERING PROVIDER ID #	
MM DD YY	MM DD YY	11	4 J3590	JZ	A	1	123 456 7890
MM DD YY	MM DD YY	11	96372	A	1	123 456 7890	

25. FEDERAL TAX ID, NUMBER SSN EIN

26. PATIENT'S ACCOUNT NO.

27. ACCEPT ASSIGNMENT? (For gdn, drms, pos base)

28. TOTAL CHARGE \$

29. AMOUNT PAID \$

30. Rev'd for NUCC Use

31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREE OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)

32. SERVICE FACILITY LOCATION INFORMATION

33. BILLING PROVIDER INFO & PH # (203) 555-6543
Dr. Jones
4231 Center Road
Anytown, AS 01010

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

YESINTEK for Subcutaneous Injection

Physician Office Sample Claim Form (CMS-1500):
90 mg Subcutaneous Injection Maintenance Dose

- Box 19 ADDITIONAL CLAIM INFORMATION**
When billing an unclassified HCPCS product code such as J3590, Medicare and other payers may require additional information to be reported here, including the name of the drug, strength, and dosage. See your MAC for additional reporting requirements.
- Box 21 DIAGNOSIS**
Enter the appropriate diagnosis code (eg, K50.00 for Crohn's disease of small intestine without complications).
- Box 24A NDC INFORMATION**
If line item NDC information is required, it will be entered in the shaded portion on Row 1 of this section. Payer requirements for NDC entries may vary.
- Box 24D PROCEDURES/SERVICES/SUPPLIES**
Enter appropriate CPT and HCPCS codes and modifiers, if required.
For example: YESINTEK J3590; subcutaneous injection administration CPT 96372
Applicable Modifiers: See page 21.
- Box 24E DIAGNOSIS POINTER**
Enter the letter (A-L) from Box 21 for the diagnosis code(s) related to the service on a single line item.
- Box 24F \$ CHARGES**
Enter the total charges.
- Box 24G UNITS**
• J3590
Until a product-specific HCPCS code is assigned, report the YESINTEK product with an unclassified code such as J3590; unclassified codes are reported with a unit of 1, and additional information on dose administered is included in Box 19.
• 96372—Enter 1 unit for injection

It is the healthcare provider's responsibility to determine the appropriate codes and modifiers. Coverage, billing, and reimbursement policies may vary by payer, plan, and setting of care.

Sample Claim Forms (continued)

1 Anytown Hospital 160 Main Street Anytown, Anystate 01010		2 Pay-to-name Pay-to-address Pay-to-city/state		3 PAC CHL 1 XX-XXXX 4 BILL REG # DOE 1234-97		5 FEDI TAX NO. 010001010		6 STATEMENT COVERS PERIOD FROM THROUGH		7	
8 PATIENT NAME Doe, Jane A. (ID)		9 PATIENT ADDRESS 1234 Main Street		10 IL 101010		11 US					
12 BIRTHDATE 01-15-52		13 SEX F		14 ADMISSION DATE 13 HR		15 SRC		16 DHR		17 STATE	
18		19		20		21		22		23	
24		25		26		27		28		29	
30		31		32		33		34		35	
36		37		38		39		40		41	
42		43		44		45		46		47	
48		49		50		51		52		53	
54		55		56		57		58		59	
60		61		62		63		64		65	
66		67		68		69		70		71	
72		73		74		75		76		77	
78		79		80		81		82		83	
84		85		86		87		88		89	
90		91		92		93		94		95	
96		97		98		99		100		101	
102		103		104		105		106		107	
108		109		110		111		112		113	
114		115		116		117		118		119	
120		121		122		123		124		125	
126		127		128		129		130		131	
132		133		134		135		136		137	
138		139		140		141		142		143	
144		145		146		147		148		149	
150		151		152		153		154		155	
156		157		158		159		160		161	
162		163		164		165		166		167	
168		169		170		171		172		173	
174		175		176		177		178		179	
180		181		182		183		184		185	
186		187		188		189		190		191	
192		193		194		195		196		197	
198		199		200		201		202		203	
204		205		206		207		208		209	
210		211		212		213		214		215	
216		217		218		219		220		221	
222		223		224		225		226		227	
228		229		230		231		232		233	
234		235		236		237		238		239	
240		241		242		243		244		245	
246		247		248		249		250		251	
252		253		254		255		256		257	
258		259		260		261		262		263	
264		265		266		267		268		269	
270		271		272		273		274		275	
276		277		278		279		280		281	
282		283		284		285		286		287	
288		289		290		291		292		293	
294		295		296		297		298		299	
300		301		302		303		304		305	
306		307		308		309		310		311	
312		313		314		315		316		317	
318		319		320		321		322		323	
324		325		326		327		328		329	
330		331		332		333		334		335	
336		337		338		339		340		341	
342		343		344		345		346		347	
348		349		350		351		352		353	
354		355		356		357		358		359	
360		361		362		363		364		365	
366		367		368		369		370		371	
372		373		374		375		376		377	
378		379		380		381		382		383	
384		385		386		387		388		389	
390		391		392		393		394		395	
396		397		398		399		400		401	
402		403		404		405		406		407	
408		409		410		411		412		413	
414		415		416		417		418		419	
420		421		422		423		424		425	
426		427		428		429		430		431	
432		433		434		435		436		437	
438		439		440		441		442		443	
444		445		446		447		448		449	
450		451		452		453		454		455	
456		457		458		459		460		461	
462		463		464		465		466		467	
468		469		470		471		472		473	
474		475		476		477		478		479	
480		481		482		483		484		485	
486		487		488		489		490		491	
492		493		494		495		496		497	
498		499		500		501		502		503	
504		505		506		507		508		509	
510		511		512		513		514		515	
516		517		518		519		520		521	
522		523		524		525		526		527	
528		529		530		531		532		533	
534		535		536		537		538		539	
540		541		542		543		544		545	
546		547		548		549		550		551	
552		553		554		555		556		557	
558		559		560		561		562		563	
564		565		566		567		568		569	
570		571		572		573		574		575	
576		577		578		579		580		581	
582		583		584		585		586		587	
588		589		590		591		592		593	
594		595		596		597		598		599	
600		601		602		603		604		605	
606		607		608		609		610		611	
612		613		614		615		616		617	
618		619		620		621		622		623	
624		625		626		627		628		629	
630		631		632		633		634		635	
636		637		638		639		640		641	
642		643		644		645		646		647	
648		649		650		651		652		653	
654		655		656		657		658		659	
660		661		662		663		664		665	
666		667		668		669		670		671	
672		673		674		675		676		677	
678		679		680		681		682		683	
684		685		686		687		688		689	
690		691		692		693		694		695	
696		697		698		699		700		701	
702		703		704		705		706		707	
708		709		710		711		712		713	
714		715		716		717		718		719	
720		721		722		723		724		725	
726		727		728		729		730		731	
732		733		734		735		736		737	
738		739		740		741		742		743	
744		745		746		747		748		749	
750		751		752		753		754		755	
756		757		758		759		760		761	
762		763		764		765		766		767	
768		769		770		771		772		773	
774		775		776		777		778		779	
780		781		782		783		784		785	
786		787		788		789		790		791	
792		793		794		795		796		797	
798		799		800		801		802		803	
804		805		806		807		808		809	
810		811		812		813		814		815	
816		817		818		819		820		821	
822		823		824		825		826		827	
828		829		830		831		832		833	
834		835		836		837		838		839	
840		841		842		843		844		845	
846		847		848		849		850		851	
852		853		854		855		856		857	
858		859		860		861		862		863	
864		865		866		867		868		869	
870		871		872		873		874		875	
876		877		878		879		880		881	
882		883		884		885		886		887	
888		889		890		891		892		893	
894		895		896		897		898		899	
900		901		902		903		904		905	
906		907		908		909		910		911	
912		913		914		915		916		917	
918		919		920		921					



PLAQUE PSORIASIS AND PSORIATIC ARTHRITIS

YESINTEK SUBCUTANEOUS INJECTION

Indicated for the treatment of adult patients and pediatric patients 6 years and older with moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy, or adult patients with active psoriatic arthritis (PsA).¹

Dosing and Administration¹

YESINTEK dosing for plaque psoriasis or psoriatic arthritis may be weight-based. Induction and maintenance doses are administered by subcutaneous injection.

TABLE 1. YESINTEK SUBCUTANEOUS INJECTION DOSING TABLE¹

Indication	Patient Weight	Induction	Maintenance	YESINTEK Vials 45 mg/0.5 mL
Plaque Psoriasis Adult	100 kg or less	45 mg	45 mg at 4 weeks after initial dose then 45 mg every 12 weeks	1 vial
	More than 100 kg	90 mg	90 mg at 4 weeks after initial dose then 90 mg every 12 weeks	2 vials
Plaque Psoriasis Pediatric Patients (6-17 years old)	Less than 60 kg	0.75 mg/kg	0.75 mg/kg at 4 weeks after initial dose then 0.75 mg/kg every 12 weeks	<1 vial
	60 kg-100 kg	45 mg	45 mg at 4 weeks after initial dose then 45 mg every 12 weeks	1 vial
	More than 100 kg	90 mg	90 mg at 4 weeks after initial dose then 90 mg every 12 weeks	2 vials
Psoriatic Arthritis	All adult patients (see exception below)	45 mg	45 mg at 4 weeks after initial dose then 45 mg every 12 weeks	1 vial
	Patients with co-existent moderate-to-severe plaque psoriasis weighing more than 100 kg	90 mg	90 mg at 4 weeks after initial dose then 90 mg every 12 weeks	2 vials

There are 2 available dosage forms for subcutaneous injection:

- 45 mg/0.5 mL or 90 mg/mL single-dose prefilled syringe
- 45 mg/0.5 mL single-dose vial



Single-dose vial for subcutaneous injection

Dosing and Administration¹ (continued)

This section of the Coding and Billing Guide will provide coding and product information related to the subcutaneous injection of the 45 mg/0.5 mL single-dose vial only.

General Considerations for Administration

- YESINTEK is intended for use under the guidance and supervision of a healthcare provider. YESINTEK should only be administered to patients who will be closely monitored and have regular follow-up visits with a healthcare provider. The appropriate dose should be determined by a healthcare provider using the patient's current weight at the time of dosing. In pediatric patients, it is recommended that YESINTEK be administered by a healthcare provider. If a healthcare provider determines that it is appropriate, a patient may self-inject or a caregiver may inject YESINTEK after proper training in subcutaneous injection technique. Instruct patients to follow the directions provided in the Instructions for Use included with their medication.
- It is recommended that each injection be administered at a different anatomic location (such as upper arms, gluteal regions, thighs, or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, or indurated. When using the single-dose vial, a 1-mL syringe with a 27-gauge, ½-inch needle is recommended.
- Prior to administration, visually inspect YESINTEK for particulate matter and discoloration. YESINTEK is a colorless to pale yellow solution. Do not use YESINTEK if it is discolored or cloudy, or if other particulate matter is present. YESINTEK does not contain preservatives; therefore, discard any unused product remaining in the vial and/or syringe.
- Each vial of YESINTEK for subcutaneous use contains 45 mg of ustekinumab in 0.5 mL. Determine the dose and number of YESINTEK vials needed based on the indication.
- Draw required dose using the Instructions for Use.



Single-dose vial
for subcutaneous injection

Coding

ICD-10-CM Diagnosis Codes

YESINTEK is FDA approved for the treatment of psoriatic arthritis and psoriasis. This table includes code ranges and codes that may be applicable for these indications; additional codes may apply. For the codes represented here, it is necessary to code to the greatest level of specificity; a code is invalid if it does not include the full number of required characters.²

TABLE 2. ICD-10-CM DIAGNOSIS CODES*—PSORIATIC ARTHRITIS AND PSORIASIS	
Psoriatic Arthritis ¹⁴	
L40.50	Arthropathic psoriasis, unspecified
L40.51	Distal interphalangeal psoriatic arthropathy
L40.52	Psoriatic arthritis mutilans
L40.53	Psoriatic spondylitis
L40.54	Psoriatic juvenile arthropathy
L40.59	Other psoriatic arthropathy
Psoriasis ¹⁴	
L40.0	Psoriasis vulgaris
L40.9	Psoriasis, unspecified

*These codes are not intended to be promotional, nor to encourage or suggest a use of the drug that is inconsistent with FDA-approved use. The codes provided are not exhaustive and additional codes may apply.



Single-dose vial for subcutaneous injection

Coding (continued)

National Drug Code (NDC)

Drugs and biologics approved by the FDA are assigned a 3-segment NDC number that is specific to the labeler (manufacturer), product (a specific drug, strength, and dosage formulation), and package size. YESINTEK and unbranded ustekinumab have been assigned 10-digit NDCs as listed in the prescribing information.⁶

Although the FDA uses a 10-digit format, the 11-digit format is required by HIPAA for claims submission without hyphens or punctuation marks.

TABLE 3. YESINTEK SINGLE-DOSE VIAL FOR SUBCUTANEOUS INJECTION NDC¹

10-Digit NDC (5-3-2 format)	11-Digit NDC (5-4-2 format)	Description
83257-024-11	83257-0024-11	Single-dose vial containing 45 mg of YESINTEK per 0.5 mL solution

NDC Units

The NDC unit of measure is determined by how the drug is supplied. In the outpatient setting, UN (unit) applies to drugs supplied in a vial in powder form, requiring reconstitution before administration, and mL (milliliters) applies to drugs supplied in liquid form.⁶ NDC units dispensed are based on the packaging and numeric quantity administered to the patient (see examples below using 45 mg and 90 mg doses of YESINTEK and unbranded ustekinumab-kfce).

Accurate NDC coding typically requires reporting the following components⁶:

- The NDC with 11 digits in a 5-4-2 format (this may require converting a 10-digit NDC)
- The correct NDC unit of measure (ie, UN, ML)
- The number of NDC units dispensed
- The qualifier, N4, in front of the NDC

Example: the coding format for a 45 mg dose of YESINTEK from single-dose vials: **N483257003211 ML0.5**

Coding (continued)

Healthcare Common Procedure Code System (HCPCS) Level II Codes

HCPCS Level II product codes are used to report FDA-approved biologic products. The Centers for Medicare and Medicaid Services (CMS) has not yet assigned a product-specific HCPCS code for YESINTEK. Therefore, until a specific code is assigned, report YESINTEK for subcutaneous injection with an unspecified HCPCS code. When reporting unspecified codes on claims, additional information may be required to be reported, including the NDC, strength and dose, and route of administration. Refer to your payer’s documentation for additional information on billing unspecified HCPCS codes. An application for a product-specific HCPCS code for YESINTEK for subcutaneous use has been submitted.

TABLE 4. HCPCS CODES FOR YESINTEK⁵

Code	Description	For	Site of Care
J3490	Unclassified drugs	YESINTEK/ustekinumab-kfce, subcutaneous injection	All sites of care
J3590	Biologic not otherwise classified	YESINTEK/ustekinumab-kfce, subcutaneous injection	All sites of care
C9399	Unclassified drugs or biologics	YESINTEK/ustekinumab-kfce, subcutaneous injection	Hospital outpatient department

It is the healthcare provider’s responsibility to determine the appropriate codes, units, and modifiers. Coverage, billing, and reimbursement policies may vary by payer, plan, and setting of care. Contact your payer for additional information on coverage and billing for YESINTEK.

Coding (continued)

HCPCS Level I / Current Procedural Technology (CPT®) Codes

Drug administration services are reported on claim forms in both the physician office (CMS-1500) and hospital outpatient (CMS-1450) sites of care using the CPT coding system. The following code may be used to report the subcutaneous administration of YESINTEK:

TABLE 5. CPT CODE FOR YESINTEK FOR SUBCUTANEOUS INJECTION⁷

Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous injection or intramuscular

Please refer to the summary of code modifiers on page 31 for details.

It is the healthcare provider’s responsibility to determine the appropriate codes, units, and modifiers. Coverage, billing, and reimbursement policies may vary by payer, plan, and setting of care. Contact your payer for additional information on coverage and billing for YESINTEK.

Revenue Codes

National Uniform Billing Committee (NUBC) hospital revenue codes are required to bill for hospital services and items like biologics. Each line item on a CMS-1450 (UB-04) or the 837I electronic claim format, must have an assigned revenue code. The revenue codes below may be applicable to hospital claims for YESINTEK for subcutaneous use:

TABLE 6. REVENUE CODES FOR YESINTEK FOR SUBCUTANEOUS INJECTION⁸

Code	Description
0636	Pharmacy, drugs requiring detailed coding
0940	Other therapeutic services - General

Coding (continued)

HCPCS and Current Procedural Technology (CPT®) Modifiers

Modifiers are used to report or indicate that a service or procedure has been altered by some specific circumstance, but not changed in its definition or code. They provide additional information about a service or procedure. Table 7 summarizes modifiers that may be applicable to coding and billing YESINTEK intravenous (IV) use in physician offices and hospital outpatient departments (HOPDs).

TABLE 7. SUMMARY OF CODE MODIFIERS

Modifier	Description	Indication and Placement	CMS-1500 (Item 24D)	CMS-1450 (Box 44)
25	Significant, separately identifiable evaluation and management (E/M) service by the same physician or other qualified healthcare professional on the same day of the procedure or other service ⁷	<ul style="list-style-type: none"> Reported if patient requires distinct E/M service in addition to the infusion procedure⁷ Must be substantiated by documentation that supports the relevant criteria for the reported E/M code⁷ Append the modifier to the appropriate E/M code⁷ 	✓ Required by Medicare	✓ Required by Medicare
PO*	Excepted services provided at an off-campus, outpatient, provider-based department of a hospital ⁵	<ul style="list-style-type: none"> To be reported on each claim line for excepted services furnished in an off-campus, provider-based department of a hospital and billed on an institutional claim⁹ 	N/A	✓ Required by Medicare
PN*	Non-excepted service provided at an off-campus, outpatient, provider-based department of a hospital ⁵	<ul style="list-style-type: none"> To be reported on each claim line for non-excepted services furnished in an off-campus provider-based department of a hospital and billed on an institutional claim⁹ 	N/A	✓ Required by Medicare
JW	Drug amount discarded/not administered to any patient ⁵	<ul style="list-style-type: none"> Applies only to the unused drug that is discarded after applicable dose has been administered from a single-use vial¹⁰ Append the modifier to the drug code on a line separate from that reporting the administered dose¹⁰ Required to be reported with unclassified HCPCS codes J3490 or J3590, when the product is administered in a physician's office or freestanding center¹⁰ Does not apply to C9399 reporting for hospital outpatient claims¹⁰ 	✓ Required by Medicare	✓ Required by Medicare
JZ	Zero drug amount discarded/not administered to any patient ⁵	<ul style="list-style-type: none"> To be used for single-dose containers or single-use packages when the entire amount has been administered to the patient (no wastage)¹¹ Required to be reported with unclassified HCPCS codes J3490 or J3590, when the product is administered in a physician's office or freestanding center¹⁰ Does not apply to C9399 reporting for hospital outpatient claims¹⁰ 	✓ Required by Medicare	✓ Required by Medicare
TB	Drug or biological acquired with 340B Drug Pricing Program discount ⁵	<ul style="list-style-type: none"> Must be reported by hospitals designated as "select entities" (rural sole community hospitals, children's hospitals, and PPS-exempt cancer hospitals) to identify 340B drugs for informational purposes⁹ To be reported on the same claim line as the drug HCPCS code for all 340B acquired drugs⁹ 	N/A	✓ Required by Medicare

*Neither the PO nor the PN modifier is to be reported for dedicated emergency departments, remote locations or satellite facilities of a hospital, or a provider-based department that is on campus.⁹

Sample Claim Forms

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE MEDICAD TRICARE CHAMPVA GROUP HEALTH PLAN FECA OTHER 1a. INSURED'S ID. NUMBER (For Program in Item 1)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial) Doe, Jane A. 3. PATIENT'S BIRTH DATE (MM | DD | YY) 01 | 15 | 52 SEX M F 4. INSURED'S NAME (Last Name, First Name, Middle Initial) Doe, Jane A.

5. PATIENT'S ADDRESS (No., Street) 1234 Main Street 6. PATIENT RELATIONSHIP TO INSURED Self Spouse Child Other 7. INSURED'S ADDRESS (No., Street) 1234 Main Street

8. RESERVED FOR NUCC USE 9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial) 10. IS PATIENT'S CONDITION RELATED TO: a. EMPLOYMENT? (Current or Previous) YES NO b. AUTO ACCIDENT? YES NO c. OTHER ACCIDENT? YES NO 11. INSURED'S POLICY GROUP OR FECA NUMBER a. INSURED'S DATE OF BIRTH (MM | DD | YY) M F b. OTHER CLAIM ID (Designated by NUCC) c. INSURANCE PLAN NAME OR PROGRAM NAME d. IS THERE ANOTHER HEALTH BENEFIT PLAN? YES NO #yes, complete items 9, 9a, and 9d.

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below. SIGNED: _____ DATE: _____ 13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below. SIGNED: _____

14. DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (LMP) (MM | DD | YY) QUAL. 15. OTHER DATE (MM | DD | YY) 16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION (FROM | MM | DD | YY TO | MM | DD | YY) 17. NAME OF REFERRING PROVIDER OR OTHER SOURCE Dr. Smith 17a. NPI 123 456 7890 17b. NPI 17c. NPI 18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES (FROM | MM | DD | YY TO | MM | DD | YY) 19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC) 20. OUTSIDE LAB? YES NO \$ CHARGES

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Indicate A-E, to service line below (24E)) ICD-10 Code: L40.50 22. SUBMISSION CODE ORIGINAL REF. NO. 23. PREFIX NUMBER

A. DATE OF SERVICE (MM DD YY)	B. PLACE OF SERVICE (S, H, O, U, R, S, I, C, I, T, Y)	C. PROCEDURE, SERVICE, OR SUPPLY (CPT/HCPCS, MOONBER)	D. DIAGNOSIS POINTER	E. \$ CHARGES	F. UNITS	G. DAYS OR UNITS	H. NPI	I. RENDERING PROVIDER ID. #
11 11 11	11	J3590	A	123 456 7890	1			123 456 7890
11 11 11	11	96372	A	123 456 7890	1			123 456 7890

25. FEDERAL TAX ID, NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? (For gdn, drms, pos 2820) YES NO 28. TOTAL CHARGE \$ 29. AMOUNT PAID \$ 30. Rev'd for NUCC Use

31. SIGNATURE OF PHYSICIAN OR SUPPLIER (Including degrees or credentials) (I certify that the statements on the reverse apply to this bill and are made a part thereof.) SIGNED: _____ DATE: _____ 32. SERVICE FACILITY LOCATION INFORMATION a. b. 33. BILLING PROVIDER INFO & P# (203) 555-6543 Dr. Jones 4231 Center Road Anytown, AS 01010 a. 123 456 7890 b.

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

YESINTEK for Subcutaneous Injection Physician Office Sample Claim Form (CMS-1500)

- Box 19 ADDITIONAL CLAIM INFORMATION**
When billing an unclassified HCPCS product code such as J3590, Medicare and other payers may require additional information to be reported here, including the name of the drug, strength, and dosage. See your MAC for additional reporting requirements.
- Box 21 DIAGNOSIS**
Enter the appropriate diagnosis code (eg, L40.50 for Arthropathic psoriasis, unspecified).
- Box 24A NDC INFORMATION**
If line item NDC information is required, it will be entered in the shaded portion on Row 1 of this section. Payer requirements for NDC entries may vary.
- Box 24D PROCEDURES/SERVICES/SUPPLIES**
Enter appropriate CPT and HCPCS codes and modifiers, if required. For example: YESINTEK J3590; subcutaneous injection administration.
Applicable Modifiers: See page 31.
- Box 24E DIAGNOSIS POINTER**
Enter the letter (A-L) from Box 21 for the diagnosis code(s) related to the service on a single line item.
- Box 24F \$ CHARGES**
Enter the total charges.
- Box 24G UNITS**
 - J3590
Until a product-specific HCPCS code is assigned, report the YESINTEK product with an unclassified code such as J3590; unclassified codes are reported with a unit of 1, and additional information on dose administered is included in Box 19.
 - 96372—Enter 1 unit for injection

It is the healthcare provider's responsibility to determine the appropriate codes and modifiers. Coverage, billing, and reimbursement policies may vary by payer, plan, and setting of care.

Sample Claim Forms (continued)

YESINTEK for Subcutaneous Injection

HOPD Sample Claim Form (CMS-1450) (UB-04)

1 Anytown Hospital 160 Main Street Anytown, Anystate 01010		2 Pay-to-name Pay-to-address Pay-to-city/state 010001010		3a PAC CHIEF XX-XXXX		3b BILLING REG.# DOE 1234-97		4 BILL OF BILL	
8 PATIENT NAME Doe, Jane A. (ID)		9 PATIENT ADDRESS 1234 Main Street		10 IL		11 IL		12 101010	
13 Doe, Jane A.		14 Anytown		15 IL		16 IL		17 101010	
18 01-15-52		19 F		20		21		22	
23		24		25		26		27	
28		29		30		31		32	
33		34		35		36		37	
38		39		40		41		42	
43		44		45		46		47	
48		49		50		51		52	
53		54		55		56		57	
58		59		60		61		62	
63		64		65		66		67	
68		69		70		71		72	
73		74		75		76		77	
78		79		80		81		82	
83		84		85		86		87	
88		89		90		91		92	
93		94		95		96		97	
98		99		00		01		02	
03		04		05		06		07	
08		09		10		11		12	
13		14		15		16		17	
18		19		20		21		22	
23		24		25		26		27	
28		29		30		31		32	
33		34		35		36		37	
38		39		40		41		42	
43		44		45		46		47	
48		49		50		51		52	
53		54		55		56		57	
58		59		60		61		62	
63		64		65		66		67	
68		69		70		71		72	
73		74		75		76		77	
78		79		80		81		82	
83		84		85		86		87	
88		89		90		91		92	
93		94		95		96		97	
98		99		00		01		02	
03		04		05		06		07	
08		09		10		11		12	
13		14		15		16		17	
18		19		20		21		22	
23		24		25		26		27	
28		29		30		31		32	
33		34		35		36		37	
38		39		40		41		42	
43		44		45		46		47	
48		49		50		51		52	
53		54		55		56		57	
58		59		60		61		62	
63		64		65		66		67	
68		69		70		71		72	
73		74		75		76		77	
78		79		80		81		82	
83		84		85		86		87	
88		89		90		91		92	
93		94		95		96		97	
98		99		00		01		02	
03		04		05		06		07	
08		09		10		11		12	
13		14		15		16		17	
18		19		20		21		22	
23		24		25		26		27	
28		29		30		31		32	
33		34		35		36		37	
38		39		40		41		42	
43		44		45		46		47	
48		49		50		51		52	
53		54		55		56		57	
58		59		60		61		62	
63		64		65		66		67	
68		69		70		71		72	
73		74		75		76		77	
78		79		80		81		82	
83		84		85		86		87	
88		89		90		91		92	
93		94		95		96		97	
98		99		00		01		02	
03		04		05		06		07	
08		09		10		11		12	
13		14		15		16		17	
18		19		20		21		22	
23		24		25		26		27	
28		29		30		31		32	
33		34		35		36		37	
38		39		40		41		42	
43		44		45		46		47	
48		49		50		51		52	
53		54		55		56		57	
58		59		60		61		62	
63		64		65		66		67	
68		69		70		71		72	
73		74		75		76		77	
78		79		80		81		82	
83		84		85		86		87	
88		89		90		91		92	
93		94		95		96		97	
98		99		00		01		02	
03		04		05		06		07	
08		09		10		11		12	
13		14		15		16		17	
18		19		20		21		22	
23		24		25		26		27	
28		29		30		31		32	
33		34		35		36		37	
38		39		40		41		42	
43		44		45		46		47	
48		49		50		51		52	
53		54		55		56		57	
58		59		60		61		62	
63		64		65		66		67	
68		69		70		71		72	
73		74		75		76		77	
78		79		80		81		82	
83		84		85		86		87	
88		89		90		91		92	
93		94		95		96		97	
98		99		00		01		02	
03		04		05		06		07	
08		09		10		11		12	
13		14		15		16		17	
18		19		20		21		22	
23		24		25		26		27	
28		29		30		31		32	
33		34		35		36		37	
38		39		40		41		42	
43		44		45		46		47	
48		49		50		51		52	
53		54		55		56		57	
58		59		60		61		62	
63		64		65		66		67	
68		69		70		71		72	
73		74		75		76		77	
78		79		80		81		82	
83		84		85		86		87	
88		89		90		91		92	
93		94		95		96		97	
98		99		00		01		02	
03		04		05		06		07	
08		09		10		11		12	
13		14		15		16		17	
18		19		20		21		22	
23		24		25		26		27	
28		29		30		31		32	
33		34		35		36		37	
38		39		40		41		42	
43		44		45		46		47	
48		49		50		51		52	
53		54		55		56		57	
58		59		60		61		62	
63		64		65		66		67	
68		69		70		71		72	
73		74		75		76		77	
78		79		80		81		82	
83		84		85		86		87	
88		89		90		91		92	
93		94		95		96		97	
98		99		00		01		02	
03		04		05		06		07	
08		09		10		11		12	
13		14		15		16		17	
18		19		20		21		22	
23		24		25		26		27	
28		29		30		31		32	
33		34		35		36		37	
38		39		40		41		42	
43		44		45		46		47	
48		49		50		51		52	
53		54		55		56		57	
58		59		60		61		62	
63		64		65		66		67	
68		69		70		71		72	
73		74		75		76		77	
78		79		80		81		82	
83		84		85		86		87	
88		89		90		91		92	
93		94		95		96		97	
98		99		00		01		02	
03		04		05		06		07	
08		09		10		11		12	
13		14		15		16		17	
18		19		20		21		22	
23		24		25		26		27	
28		29		30		31		32	
33		34		35		36		37	
38		39		40		41		42	
43		44		45		46		47	
48		49		50		51		52	
53		54		55		56		57	
58		59		60		61		62	
63		64		65					



COVERAGE & SUPPORT

Coverage Considerations

Third-party payers (eg, commercial insurers, Medicare, Medicaid) will generally cover parenteral drugs and biologics for their FDA-approved indications and the associated professional administration services. However, benefits may vary depending on the payer and the specific plan in which a patient is enrolled.

Eligibility and Coverage Criteria

Eligibility and benefit confirmation, and demonstrated medical necessity, are key to ensuring submitted claims will be covered. It is important to review the payer’s published medical policies and check the patient’s eligibility against all criteria, including patient diagnoses, treatment history for the condition, and other stipulations of coverage.

Medicare National Coverage Determinations (NCDs) and Medicare Administrative Contractors (MACs) Local Coverage Determinations (LCDs) define medical necessity requirements for Medicare coverage. These documents contain guidance on covered diagnoses, required documentation, and limitations of coverage for specific services in accordance with medical necessity.

Prior Authorization Overview

A prior authorization (PA) is a requirement imposed by a payer for the provider to obtain approval prior to administering a drug or performing a procedure or service. It is used to help payers ensure that the therapy is medically necessary and serves as a preliminary determination of coverage, but the payer reserves the right to review documentation before or after claim payment to make a final determination. Payers typically have standard processes that must be followed for healthcare providers to submit a PA request. These may include calling a specific department, filling out and faxing a form, or writing a letter of medical necessity. Evidence of medical necessity may include:

- The expected outcome of a prescribed therapy
- Potential consequences of not using that therapy
- The reason(s) why alternatives are not clinically appropriate

An adequately supported and appropriately submitted PA is more likely to result in a favorable coverage decision. If for some reason a patient cannot meet a payer’s requirements for the drug they need, they have the right to request a coverage determination, also known as requesting an exception.

Coverage Considerations (continued)

Administrative Considerations

Other considerations may be involved in a payer’s coverage policies for an item or service:

Does the payer’s contract specifically indicate the sites of care that may bill for infusion services or infused drugs?

- A small portion of payers have exclusive contracts with designated preferred providers for infusion services
- This may include certain clinics or specialty pharmacies that deliver drugs to healthcare providers or other infusion centers

Does the payer cover the therapy only when provided through a specific treatment site?

- Payers may have site-specific coverage rules that restrict provision of infused therapies
- For example, currently Medicare does not cover infusions when they are billed by Medicare-certified ambulatory surgery centers
- Payers also may restrict coverage for certain infused drugs in the home or hospital outpatient setting

Is the billing provider a “participating” member of, or “in-network” provider for, that particular plan?

- Payers contract with providers to deliver services to the plan’s members
- Providers are thus “participating” or within that plan’s network, requiring them to abide by the contract charge structure when providing care for that plan’s members

Is the plan willing to grant in-network status when a service is otherwise out of network?

- In some cases (eg, when there are no available in-network providers), health plans may grant in-network status for a provider and related services
- In such cases, the provider accepts the in-network rate and the patient will be able to access in-network cost-sharing
- It may be helpful to contact a payer to ask for a service to be converted to in-network status

If required by the plan, has the appropriate referral or prior authorization been obtained?

- Many plans require that non-emergency services be pre-approved or that a primary care physician make the referral for specialty care
- Failing to obtain appropriate referrals or pre-authorization can result in non-payment by the plan

Coverage Considerations (continued)

Exception Request

An exception request is a specific type of coverage determination that asks a payer to reconsider a coverage denial or to deviate from standard process. It provides the payer an opportunity to influence, or make more patient-specific, a coverage decision-making process when the payer's coverage policies do not meet a patient's unique needs. An exception request again requires the prescriber to submit evidence of medical necessity. It is helpful to specifically respond to the reason(s) coverage was denied (eg, drug not on formulary, dose restrictions, step therapy, etc). An exception request that is appropriately submitted and adequately supported is more likely to result in a favorable payer decision. If the request is not granted, the payer will provide the patient with a written explanation and include information about how to request an appeal.

Appeals

Appeals are a response to a payer's denial of benefits the enrollee believes they are entitled to receive. The appeals process typically includes a series of progressive steps and specific timelines. If supporting an appeal, contact the payer for guidance as individual policies may vary. Steps patients or providers can take to support an appeal include:

- Submitting supporting evidence to counter the specific reason for the denial
- Presenting the patient's story in a manner that leads to the therapeutic request (eg, events leading to current condition, results of previous therapies, expected clinical progression)
- Expressing willingness to collaborate (eg, offer contact information, invite discussion with medical director or specialist)

Following a positive coverage decision at any stage, it is important to provide feedback to the payer and reinforce that their decision resulted in a positive patient outcome.



My Biocon Biologics™ provides patient access support

In addition to this Coding & Billing Guide, Biocon Biologics offers the following services and tools to help you and your patients with YESINTEK™ from the start.



Benefits Investigation

Handles research of insurance coverage and patient cost-sharing, while providing a full summary of benefits



Bridge Program*

Helps minimize authorization-related treatment delays for existing patients and deliver prescriptions to their door



Prior Authorization (PA) Support

Helps you with verifying the enrollment status of your patient's insurance plan



IV Savings Program†

Gives eligible new patients savings up to \$100 in out-of-pocket costs associated with the initial induction dose for gastrointestinal conditions



Quick Start Program*

Provides a way for new patients to quickly begin therapy if the PA or appeal process takes 5 days or longer



Instructional Injection Video

Educates patients through a step-by-step video tutorial on how to properly inject YESINTEK

Some services listed may not be available at launch. For the latest updates on all programs, please check with My Biocon Biologics.

*Eligibility restrictions apply. For Bridge Program and Quick Start Program terms and conditions, visit www.YesintekHCP.com/bridgeprogramtermsandconditions.
†Eligibility restrictions apply. Not valid for uninsured patients or patients who are covered by a state- or federally funded healthcare program. For full terms and conditions, visit www.Yesintek.com/IVsavingsprogram.



Pay as little as \$0 in out-of-pocket costs*
For YESINTEK™ (ustekinumab-kfce) injection or ustekinumab-kfce

YES-2021E-100010-05
RxBIN:XXXXX RxCN:XXXXX RxGRP:XXXXXXXXXX RxID:XXXXXXXXXXXXXXXXXX
*Eligibility restrictions apply. For full terms and conditions, visit www.Yesintek.com/copay.

COPAY ASSISTANCE‡

We'll help you identify and enroll your eligible patients who may **pay as little as \$0** in out-of-pocket costs.

‡Eligibility restrictions apply. Not valid for uninsured patients or patients who are covered by a state- or federally funded healthcare program. For full terms and conditions, visit www.Yesintek.com/copay.



Enroll your patients today at YesintekHCP.com.

Appendix

Sample Letter of Medical Necessity

Payers may request a letter of medical necessity to support coverage of YESINTEK. The letter explains why the drug was medically necessary for the specific patient and may include supporting documentation (eg, medical records, peer-reviewed literature, prescribing information). The letter may be submitted as part of a PA request, with the claim form, or in response to a payer’s additional document request.

The following is a sample letter of medical necessity, or you may use another form or format. The letter should include patient-specific information, should be on your letterhead and signed by the prescriber, and should be submitted to a payer to support a PA request or claim for YESINTEK.

[Date]

[Insert Name of Medical Director] Insured Member Name: [Insert Member Name]
 [Insert Payer Name] Policy Number: [Insert Member Policy Number]
 [Insert Address] [Insert City, State ZIP] Group Number: [Insert Group Number]

Patient: [Insert Patient Name]
Date of Birth: [Insert Patient DOB]
Diagnosis: [Insert Diagnosis] [Insert ICD]
Dose and Frequency: [Insert Dose & Frequency]

Dear [Insert Name of Medical Director or Name of Individual Responsible for Prior Authorization],

I am writing on behalf of my patient, [Insert Patient Name], to request **authorization** to receive treatment with YESINTEK™ for [Insert Indication]. My request is supported by the following:

Summary of Patient’s Diagnosis and History

[Insert patient’s diagnosis, date of diagnosis, lab results and date, current condition]

[Insert:

- Previous therapies/procedures, including dose and duration, response to those interventions
- Description of patient’s recent symptoms/condition
- Site of medical service—include site type (eg, inpatient, hospital outpatient, outpatient clinic, private practice, or other) and rationale (eg, compliance or closely monitoring patient)
- Rationale for not using drugs that are on the plan’s formulary
- Summary of your professional opinion of the patient’s likely prognosis or disease progression without treatment with YESINTEK

Note: Exercise your medical judgment and discretion when providing a diagnosis and characterization of the patient’s medical condition.]

Rationale for Treatment

[Insert summary statement for rationale for treatment such as: considering the patient’s history, condition, and the Full Prescribing Information supporting uses of YESINTEK, I believe treatment with YESINTEK at this time is medically necessary and should be a covered and reimbursed service.]

[You may consider including documents that provide additional clinical information to support the recommendation for YESINTEK for this patient, such as the Full Prescribing Information, peer-reviewed journal articles, and clinical guidelines.]

[Given the urgent nature of this request,] please provide a timely authorization. Contact my office at [Insert Phone Number] if I can provide you with any additional information.

Sincerely,

[Insert Healthcare Provider’s Name and Participating Provider Number]

Enclosures [Include Full Prescribing Information and the additional support noted above]

Appendix (continued)

Sample Letter of Appeal

In some cases, a claim denial may be overturned after a phone call to a payer representative. If not, an appeal letter may be submitted in response to a payer's decision for underpayment or nonpayment, as detailed in the explanation of benefits (EOB) or remittance advice. In addition to filing the appeal within timely filing limits, understanding the reasons the payer denied the claim is critical for filing a successful appeal. The following sample letter of appeal or another form may be used to submit additional documentation to the patient's payer when appealing a denied claim.

[Date]

[Insert Name of Medical Director] Insured Member Name: [Insert Member Name]
 [Insert Payer Name] Policy Number: [Insert Member Policy Number]
 [Insert Address] [Insert City, State ZIP] Group Number: [Insert Group Number]

Patient: [Insert Patient Name]
Date of Birth: [Insert Patient DOB]

Dear [Insert Contact Name],

This letter serves as a request for payment of a denied claim representing charges for YESINTEK™ (ustekinumab-kfce), a biosimilar administered to [Insert Patient Name] on [Insert Date of Service]. [Insert Patient Name] has a diagnosis of [Insert Diagnosis] [Insert ICD] and is under my treatment care. You have indicated that YESINTEK is not covered by [Insert Payer Name] because of [Insert Reason for Denial]. My request for approval is supported by the following:

Summary of Patient's Diagnosis and History

[Insert patient's diagnosis, date of diagnosis, lab results and date, current condition]

[Insert:

- Previous therapies/procedures, including dose and duration, response to those interventions
- Description of patient's recent symptoms/condition
- Site of medical service—include site type (eg, inpatient, hospital outpatient, outpatient clinic, private practice, or other) and rationale (eg, compliance or closely monitoring patient)
- Summary of your professional opinion of the patient's likely prognosis or disease progression without treatment with YESINTEK

Note: Exercise your medical judgment and discretion when providing a diagnosis and characterization of the patient's medical condition.]

Rationale for Treatment

[You may consider including documents that provide additional clinical information to support the recommendation for YESINTEK for this patient, such as the Full Prescribing Information, peer-reviewed journal articles, and clinical guidelines.]

I believe YESINTEK is a medically necessary part of [Insert Patient Name]'s treatment at this time. I request that a specialist who is familiar with YESINTEK review this appeal letter as I am confident your reconsideration of this claim would yield appropriate payment. Please contact me at [Insert Phone Number] if you require any additional information.

Thank you in advance for your immediate attention to this request.

Sincerely,

[Insert Healthcare Provider's Name and Participating Provider Number]

Enclosures [Include Full Prescribing Information and the additional support noted above]

IMPORTANT SAFETY INFORMATION

INDICATIONS

YESINTEK (ustekinumab-kfce) is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy; active psoriatic arthritis (PsA); moderately to severely active Crohn's disease (CD); moderately to severely active ulcerative colitis.

Pediatric patients 6 years and older with: moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy; active psoriatic arthritis (PsA).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

YESINTEK is contraindicated in patients with clinically significant hypersensitivity to ustekinumab or to any of the excipients.

Infections

YESINTEK may increase the risk of infections and reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections in patients receiving ustekinumab.

Serious infections requiring hospitalization or otherwise clinically significant infections:

- Plaque Psoriasis: diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis, and urinary tract infections.
- Psoriatic arthritis: cholecystitis.
- Crohn's disease: anal abscess, gastroenteritis, ophthalmic herpes zoster, pneumonia, and Listeria meningitis.
- Ulcerative colitis: gastroenteritis, ophthalmic herpes zoster, pneumonia, and listeriosis.

Treatment with YESINTEK should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to initiating use of YESINTEK in patients with a chronic infection or a history of recurrent infection.

Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur while on treatment with YESINTEK and discontinue YESINTEK for serious or clinically significant infections until the infection resolves or is adequately treated.

Theoretical Risk for Vulnerability to Particular Infections: Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria, Salmonella, and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients.

It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with ustekinumab may be susceptible to these types of infections. Consider diagnostic testing, e.g., tissue culture, stool culture, as dictated by clinical circumstances.

Pre-Treatment Evaluation of Tuberculosis (TB): Evaluate patients for TB prior to initiating treatment with YESINTEK.

Do not administer YESINTEK to patients with active tuberculosis infection. Initiate treatment of latent TB before administering YESINTEK. Closely monitor patients receiving YESINTEK for signs and symptoms of active TB during and after treatment.

Malignancies: YESINTEK is an immunosuppressant and may increase the risk of malignancy. Malignancies were reported among patients who received ustekinumab in clinical trials.

The safety of ustekinumab has not been evaluated in patients who have a history of malignancy or who have a known malignancy.

There have been reports of the rapid appearance of multiple cutaneous squamous cell carcinomas in patients receiving ustekinumab who had risk factors for developing non-melanoma skin cancer (NMSC).

IMPORTANT SAFETY INFORMATION (continued)

Malignancies: (continued)

All patients receiving YESINTEK, especially those >60 years of age, those with a history of PUVA or prolonged immunosuppressant treatment, should be monitored for the appearance of NMSC.

Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with ustekinumab. If an anaphylactic or other clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue YESINTEK.

Posterior Reversible Encephalopathy Syndrome (PRES): Two cases of posterior reversible encephalopathy syndrome (PRES), also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), were reported in clinical trials. Cases have also been reported in post-marketing experience in patients with psoriasis, psoriatic arthritis and Crohn's disease. Clinical presentation included headaches, seizures, confusion, visual disturbances, and imaging changes consistent with PRES a few days to several months after ustekinumab initiation. A few cases reported latency of a year or longer. Patients recovered with supportive care following withdrawal of ustekinumab.

Monitor all patients treated with YESINTEK for signs and symptoms of PRES. If PRES is suspected, promptly administer appropriate treatment and discontinue YESINTEK.

Immunizations: Prior to initiating therapy with YESINTEK, patients should receive all age-appropriate immunizations as recommended by current immunization guidelines. Patients being treated with YESINTEK should avoid receiving live vaccines. Avoid administering BCG vaccines during treatment with YESINTEK or for one year prior to initiating treatment or one year following discontinuation of treatment. Caution is advised when administering live vaccines to household contacts of patients receiving YESINTEK because of the potential risk for shedding from the household contact and transmission to patient.

Non-live vaccinations received during a course of YESINTEK may not elicit an immune response sufficient to prevent disease.

Noninfectious Pneumonia: Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia have been reported during post-approval use of ustekinumab. Clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses. Serious outcomes have included respiratory failure and prolonged hospitalization. Patients improved with discontinuation of therapy and, in certain cases, administration of corticosteroids. If diagnosis is confirmed, discontinue YESINTEK and institute appropriate treatment.

Allergen Immunotherapy: YESINTEK may decrease the protective effect of allergen immunotherapy (decrease tolerance) which may increase the risk of an allergic reaction to a dose of allergen immunotherapy. Therefore, caution should be exercised in patients receiving or who have received allergen immunotherapy, particularly for anaphylaxis.

Most Common Adverse Reactions

- Psoriasis: nasopharyngitis, upper respiratory tract infection, headache, and fatigue.
- Crohn's Disease, induction: vomiting.
- Crohn's Disease, maintenance: nasopharyngitis, injection site erythema, vulvovaginal candidiasis/mycotic infection, bronchitis, pruritus, urinary tract infection, and sinusitis.
- Ulcerative colitis, induction: nasopharyngitis
- Ulcerative colitis, maintenance: nasopharyngitis, headache, abdominal pain, influenza, fever, diarrhea, sinusitis, fatigue, and nausea

References

1. YESINTEK. Prescribing information. Biocon Biologics Inc; 2024.
2. Centers for Medicare & Medicaid Services. ICD-10-CM official guidelines for coding and reporting: FY 2025. (October 1, 2024-September 30, 2025). Updated October 1, 2024. Accessed January 29, 2025. <https://www.cms.gov/files/document/fy-2025-icd-10-cm-coding-guidelines.pdf>
3. ICD10data.com. Crohn's disease [regional enteritis]. Accessed January 29, 2025. <https://www.icd10data.com/ICD10CM/Codes/K00-K95/K50-K52/K50->
4. ICD10data.com. Ulcerative colitis. Accessed January 29, 2025. <https://www.icd10data.com/ICD10CM/Codes/K00-K95/K50-K52/K51->
5. American Medical Association. *HCPCS Level II: Professional 2025*. American Medical Association; 2025.
6. United Healthcare. National drug codes requirement for claims submissions. Accessed January 29, 2025. <https://www.uhcprovider.com/content/dam/provider/docs/public/complan/nj/references/NJ-National-Drug-Codes-Req-FAQ.pdf>
7. American Medical Association. *CPT® 2025: Professional Edition*. American Medical Association; 2024.
8. Noridian Healthcare Solutions. Revenue codes. Last updated March 18, 2024. Accessed January 29, 2025. <https://med.noridianmedicare.com/web/jea/topics/claim-submission/revenue-codes>
9. Centers for Medicare & Medicaid Services. Part B hospital (including inpatient hospital Part B and OPPTS). In: *Medicare Claims Processing Manual*. Chapter 4. Revised November 14, 2024. Accessed January 29, 2025. <https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c04.pdf>
10. Centers for Medicare & Medicaid Services. Drugs and biologicals. In: *Medicare Claims Processing Manual*. Chapter 17. Revised February 15, 2024. Accessed January 29, 2025. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c17.pdf>
11. Centers for Medicare & Medicaid Services. Medicare Program. Discarded drugs and biologicals: JW modifier and JZ modifier policy frequently asked questions. Updated November 2023. Accessed January 29, 2025. <https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf>
12. Centers for Medicare & Medicaid Services. Physicians/nonphysician practitioners. In: *Medicare Claims Processing Manual*. Chapter 12. Revised December 19, 2024. Accessed January 29, 2025. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c12.pdf>
13. Centers for Medicare & Medicaid Services. Completing and processing the Form CMS-1450 data set. In: *Medicare Claims Processing Manual*. Chapter 25. Revised December 20, 2023. Accessed January 29, 2025. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c25.pdf>
14. ICD10Data.com. Psoriasis. Accessed January 29, 2025. <https://www.icd10data.com/ICD10CM/Codes/L00-L99/L40-L45/L40->

YESINTEK and the Yesintek Logo are trademarks of Biocon Biologics Limited.

BIOCON BIOLOGICS and the Biocon Biologics Logo are registered trademarks of Biocon Biologics Limited.

MY BIOCON BIOLOGICS and the My Biocon Biologics Logo are trademarks of Biocon Biologics Limited.

CPT® is a registered trademark of the American Medical Association.

Stelara is a registered trademark of Johnson & Johnson.

© 2025 Biocon Biologics Inc. All Rights Reserved. YES-2024-00036-US

43 | Please refer to the **Dosage and Administration** section of the **Full Prescribing Information** and to the **Instructions for Use** for complete information on how to prepare and administer YESINTEK. Please see **Important Safety Information** for YESINTEK on pages 41 and 42.

